Fibroblast Growth Factor Receptor (FGFR) Signaling in GIST and Soft Tissue Sarcomas

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Sarcomas are rare cancers from mesenchymal tissues with few treatment options.
• Alterations in the fibroblast growth factor receptor (FGFR) pathway are increasingly recognized in sarcoma subtypes.
• These alterations include genetic mutations, translocations, amplifications, and overexpression.

Purpose of the Study:

• To review FGFR pathway alterations in sarcoma.
• To evaluate preclinical and clinical evidence for FGFR inhibitors in sarcoma.
• To discuss limitations and future directions for FGFR-targeted therapy in sarcoma.

Main Methods:

• Literature review of studies on FGFR alterations in sarcoma.
• Analysis of preclinical data on FGFR inhibitors.
• Examination of clinical trial data involving sarcoma patients and FGFR inhibitors.

Main Results:

• FGFR pathway alterations are present in various sarcoma subtypes like GIST, rhabdomyosarcoma, and liposarcoma.
• Preclinical studies show potential for FGFR inhibitors, with some multi-target TKIs demonstrating activity.
• Clinical trials have limited sarcoma patient enrollment, and selective FGFR inhibitors show low efficacy.

Conclusions:

• Targeting the FGFR pathway is a potential therapeutic strategy for sarcomas.
• Current clinical efficacy of FGFR inhibitors in sarcoma is suboptimal.
• Biomarker stratification is crucial to identify sarcoma patients who may benefit from FGFR-targeted therapies.